A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine Rituximab High Dose Cytarabine and Acalabrutinib (BR/CR-A) and 3.) Bendamustine Rituximab and Acalabrutinib (BR-A) in Patients = 70 years old with Untreated Mantle Cell Lymphoma

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.